Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Nausea and Vomiting

Nausea and Vomiting

61

Pipeline Programs↗

50

Active Trials↗

44

Companies Involved↗

Nausea and vomiting is a moderately active landscape with 61 programs across 44 companies. The most active players are Vanda Pharmaceuticals. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

56/100

Mech. Concentration

33/100

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Vanda Pharmaceuticals

1 program

Pipeline

Programs by Phase

Preclinical53

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Doxorubicin Hydrochloride

Pfizer

Cyclophosphamide

Baxter Healthcare Corporation

Lorazepam

Bausch Health Americas, Inc.

Desflurane

Baxter Healthcare Corporation

Phase 1

No programs

Phase 2

No programs

Phase 38

Nab-Paclitaxel

Bristol-Myers Squibb

Gemcitabine

Johnson & Johnson

Thalidomide

Bristol-Myers Squibb

Tradipitant

Vanda Pharmaceuticals

Amisulpride IV Treatment

Benaroya Research Institute

Approved

No programs

Analysis

Trial Status

402

clinical trials

Completed261 · 65%

Unknown status57 · 14%

Recruiting27 · 7%

Terminated25 · 6%

Not yet recruiting20 · 5%

Withdrawn8 · 2%

Other4 · 1%

Clinical Trials

Trial Activity

402 trials

A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)

Recruiting·HHelsinn Healthcare SA·Phase 2·NCT06904235·95 enrolled

Early Postoperative Pain and Related Outcomes After Cardiac Surgery: A Retrospective Cohort Study

Recruiting·Antalya Training and Research Hospital·N/A·NCT07804732·99 enrolled

Time-to-first-rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy: a Randomized, Triple-Blind, Superiority Trial

Recruiting·Faisalabad Medical University·Approved·NCT07638527·264 enrolled

Pain and Nausea in the Post-Anaesthesia Care Unit After Bariatric Surgery: A Registry Study Linking the Swedish Perioperative Register (SPOR) and the Scandinavian Obesity Surgery Registry (SOReg)

Recruiting·UUmeå University·N/A·NCT07797374·30,000 enrolled

Risk of Early Postoperative Nausea and Vomiting (PONV) - a Study With Data From the Swedish Perioperative Register (SPOR).

Recruiting·—·N/A·NCT04433676·1,500,000 enrolled

Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial

Recruiting·—·Preclinical·NCT07768124·60 enrolled

A Multicenter, Exploratory Clinical Study of the Efficacy and Safety of Phentolamine and Palonosetron for the Prevention of Nausea and Vomiting Associated With Recom-Trastuzumab Therapy

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07726433·56 enrolled

TMS Neuromodulation of Brain-to-Stomach Circuits in Chronic Nausea

Recruiting·—·Preclinical·NCT07276035·219 enrolled

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan in Breast Cancer Palliative Therapy

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07716189·74 enrolled

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Combined With Cyclophosphamide in Breast Cancer Adjuvant Chemotherapy

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07716176·74 enrolled

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound in Pancreatic Cancer Treatment

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07716228·74 enrolled

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

Recruiting·MMontefiore Medical Center·Phase 2/3·NCT06382012·250 enrolled

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Recruiting·—·Phase 3·NCT07208305·222 enrolled

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Recruiting·—·N/A·NCT06080880·98 enrolled

A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population

Recruiting·—·Phase 3·NCT06585540·100 enrolled

Page 1 of 27

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)